Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Multiple Sclerosis, a chronic inflammatory demyelinating disease of the central nervous system, involves an increased expression of monocyte chemotactic protein 1 MCP1-/CCL2. For exerting its chemotactic effects, chemokine binding to glycosaminoglycans (GAGs) is required and therefore this interaction represents a potential target for therapeutic intervention. We have designed an anti-inflammatory decoy variant, Met-CCL2 (Y13A S21K Q23R), embodying increased affinity for GAGs as well as knocked-out GPCR activation properties. This non-signalling dominant-negative mutant is shown here to be able to displace wild type CCL2 from GAGs by which it is supposed to interfere with the chemokine-related inflammatory response. In vivo, the anti-inflammatory properties were successfully demonstrated in a murine model of zymosan-induced peritonitis as well as in an experimental autoimmune encephalomyelitis, a model relevant for multiple sclerosis, where the compound lead to significantly reduced clinical scores due to reduction of cellular infiltrates and demyelination in spinal cord and cerebellum. These findings indicate a promising potential for future therapeutic development.

Original publication




Journal article


Neurosci lett

Publication Date





164 - 173


Anti-inflammatory, CCL2 decoy, Experimental autoimmune encephalomyelitis, Glycosaminoglycans, Multiple sclerosis, Animals, Anti-Inflammatory Agents, Cerebellum, Chemokine CCL2, Dexamethasone, Disease Models, Animal, Encephalitis, Encephalomyelitis, Autoimmune, Experimental, Female, Glycosaminoglycans, Inhibitory Concentration 50, Male, Mice, Mice, Inbred C57BL, Monocytes, Myelin-Oligodendrocyte Glycoprotein, Peptide Fragments, Peritonitis, Spinal Cord, Zymosan